ALT Altimmune, Inc.
Healthcare$2.90-1.02%ClosedMarket Cap: $255.9M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.27
P/S
7109.62
EV/EBITDA
-2.08
DCF Value
$0.08
FCF Yield
-28.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-41519.4%
Operating Margin
-269216.7%
Net Margin
-253002.8%
ROE
-42.6%
ROA
-27.1%
ROIC
-29.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-24.2M | $-22.6M | $— | — |
| Q4 null | $26.0K | 100.0% | $-28.9M | $-27.4M | $— | — |
| FY null | $41.0K | 100.0% | $-94.5M | $-88.1M | $— | — |
| Q3 null | $5.0K | -299100.0% | $-20.9M | $-19.0M | $— | — |
| Q2 null | $5.0K | 100.0% | $-22.9M | $-22.1M | $— | — |
| Q1 null | $5.0K | 100.0% | $-21.8M | $-19.6M | $— | — |
| Q4 null | $5.0K | 100.0% | $-24.9M | $-23.2M | $— | — |
| FY null | $20.0K | 100.0% | $-103.2M | $-95.1M | $— | — |
| Q3 null | $5.0K | 100.0% | $-24.8M | $-22.8M | $— | — |
| Q2 null | $5.0K | 100.0% | $-26.7M | $-24.6M | $— | — |
| Q1 null | $5.0K | -2040.0% | $-26.8M | $-24.4M | $— | — |
| Q4 2023 | $37.0K | 100.0% | $-33.6M | $-31.6M | $-0.54 | — |